Cullinan Therapeutics (CGEM) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed SL Science (SLBT) over the past year, gaining 165.4% versus a loss of 85.4%. Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $846.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | SLBT |
|---|---|---|
| Share price | $15.63 | $1.51 |
| Market cap | $960.59M | $846.75M |
| 1-day change | -3.82% | -0.66% |
| YTD return | +51.01% | -85.68% |
| 1-year return | +165.37% | -85.42% |
| 5-year return | -37.48% | — |
| EPS (TTM) | $-3.11 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $14.50 |
| 52-week low | $6.50 | $1.42 |
| Distance from 52-week high | -32.60% | -89.59% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +114.01% | — |
| Average volume | 871.08K | 80.93K |
| Shares outstanding | 61.46M | 560.76M |
| Employees | 109 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed SLBT by 250.8 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
CGEM vs SLBT FAQ
Which is bigger, Cullinan Therapeutics or SL Science?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $846.75M for SL Science (SLBT).
Which stock has performed better over the past year, CGEM or SLBT?
CGEM returned +165.37% over the past 12 months, compared with -85.42% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.